Symptomatic Tenosynovial Giant Cell Tumor Tgct For Which Surgical Resection Will Potentially Cause Worsening Functional Limitation Or Severe Morbidity — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for symptomatic tenosynovial giant cell tumor tgct for which surgical resection will potentially cause worsening functional limitation or severe morbidity. 30 active patents protecting 1 drugs from 1+ originators. First major cliff: 2034. Daily refresh.

Originators in Symptomatic Tenosynovial Giant Cell Tumor Tgct For Which Surgical Resection Will Potentially Cause Worsening Functional Limitation Or Severe Morbidity

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating symptomatic tenosynovial giant cell tumor tgct for which surgical resection will potentially cause worsening functional limitation or severe morbidity. Each bar = one year. Y-axis scaled to peak year (9 patents).

Approved drugs ranked by patent estate

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Related

• Symptomatic Tenosynovial Giant Cell Tumor Tgct For Which Surgical Resection Will Potentially Cause Worsening Functional Limitation Or Severe Morbidity — full disease profile
• AI Patent Landscape Report — type "symptomatic tenosynovial giant cell tumor tgct for which surgical resection will potentially cause worsening functional limitation or severe morbidity" for an AI exec memo
• Company Patent Rankings
• Biosimilar Opportunity Scanner